Board of Directors

Peter Finan
Peter Finan
Chairman
Peter Finan joined Epidarex Capital as a Venture Partner in 2014. He has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining Epidarex, Dr. Finan was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. In this role, Dr. Finan had strategic and operational oversight for the respiratory portfolio from target discovery through to proof-of-concept trials in the clinic. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Dr. Finan holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds
Tim Wilson
Tim Wilson
Chief Executive Officer
Tim’s career in the life sciences has encompassed start ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including NM Rothschild, Hambrecht and Quist, UBS, SG Cowen and Pacific Growth Equities. In 2013 he founded Longcross Advisers, a life science-focused corporate finance firm. He gained his PhD from the MRC’s Laboratory of Molecular Biology in Cambridge and a BSc (Hons) in biochemistry from Imperial College, London.
Vivienne Cox
Vivienne Cox
Chief Operating Officer
Vivienne’s career in the biotech industry includes research management roles at Wellcome Biotech and SmithKline Beecham. She was co-founder of Adprotech Ltd, a company developing novel proteins therapeutics and vaccines. In 2001 she founded UK Bioscience Consultants and has provided life science commercialization consultancy to many of the UK’s leading universities and medical institutes. She holds a PhD from Imperial College, London.
Alek Safarian
Alek Safarian
Board Member
Alek Safarian is the CEO of venture investment firm, ALSA Holdings Ltd. Alek has a diverse background in drug development spanning some 30 years. Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific. He subsequently founded Novotech, a Sydney based contract research organisation working with hundreds of clinical stage biotech companies over a 21 year period. Alek holds a B. Pharm and MBA from the University of Sydney.